(Q34576871)

3 August 2017

title

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin (English)

1 reference

3 August 2017

1 reference

1 reference

1

Rick A Bright

1 reference

3 August 2017

8

Peter Pushko

1 reference

3 August 2017

11

Gale Smith

1 reference

3 August 2017

Donald M Carter

2

1 reference

3 August 2017

Shannon Daniluk

3

1 reference

3 August 2017

Franklin R Toapanta

4

1 reference

3 August 2017

Attiya Ahmad

5

1 reference

3 August 2017

Victor Gavrilov

6

1 reference

3 August 2017

Mike Massare

7

1 reference

3 August 2017

Nutan Mytle

9

1 reference

3 August 2017

Thomas Rowe

10

1 reference

3 August 2017

Ted M Ross

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

15 February 2007

1 reference

3 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

3 August 2017

volume

25

1 reference

3 August 2017

issue

19

1 reference

3 August 2017

page(s)

3871-3878

1 reference

The economic impact of influenza in a university hospital setting

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Emerging respiratory viruses: challenges and vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Mouse strain-dependent differences in enhancement of immune responses by C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Humoral immune response to influenza vaccination in patients from high risk groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

The epidemiology and history of influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Immunogenicity and Reactogenicity of Influenza Subunit Vaccines Produced in MDCK Cells or Fertilized Chicken Eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.106

10.1016/J.VACCINE.2007.01.106

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference